Austin, TX – According to filings with the U.S. Securities and Exchange Commission, Aperiam Bio is raising $3,660,002.00 in new funding. Sources indicate as part of senior management Founder, Austin Cole played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aperiam Bio
Aperiam is taking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry. It used to be that making a new gene variant required sorting through millions, or even billions of duds to find a few winners our tools reduce that number to tens! Aperiam Bio is building partnerships with enzyme engineers and distributors to help create and share stabilized, solubilized, and catalytically optimized proteins. We take your most challenging enzymes and deliver constructs that are optimized for expression in a variety of model organisms, catalysis across many buffers, and stability against many stresses.

To learn more about Aperiam Bio, visit http://aperiambio.com/

Contact:
Austin Cole, Founder
512-318-5584
austin@aperiambio.com
https://www.linkedin.com/in/austin-cole-92803649/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved